Phase 3 Recruiting Network
This phase III trial studies how well lenalidomide and dexamethasone works with or without daratumumab in treating patients with high-risk smoldering myeloma. Drugs used in chemotherapy, such as lenalidomide and dexamethasone, work in diff…
Sponsor: ECOG-ACRIN Cancer Research Group
NCT ID: NCT03937635
Sites in Pennsylvania: - Lehigh Valley Hospital-Cedar Crest — Allentown, Pennsylvania
- Lehigh Valley Hospital - Muhlenberg — Bethlehem, Pennsylvania
- Geisinger Medical Center — Danville, Pennsylvania
- Pocono Medical Center — East Stroudsburg, Pennsylvania
- Geisinger Medical Center-Cancer Center Hazleton — Hazleton, Pennsylvania
Phase 3 Recruiting Network
This phase III trial compares the combination of four drugs (daratumumab, bortezomib, lenalidomide and dexamethasone) to the use of a three drug combination (daratumumab, lenalidomide and dexamethasone). Bortezomib may stop the growth of c…
Sponsor: ECOG-ACRIN Cancer Research Group
NCT ID: NCT04566328
Sites in Pennsylvania: - Lehigh Valley Hospital-Cedar Crest — Allentown, Pennsylvania
- Lehigh Valley Hospital - Muhlenberg — Bethlehem, Pennsylvania
- Christiana Care Health System-Concord Health Center — Chadds Ford, Pennsylvania
- Geisinger Medical Center — Danville, Pennsylvania
- Pocono Medical Center — East Stroudsburg, Pennsylvania
Phase 3 Recruiting Network
This phase III trial compares three-drug induction regimens followed by double-or single-drug maintenance therapy for the treatment of newly diagnosed multiple myeloma in patients who are not receiving a stem cell transplant and are consid…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT05561387
Sites in Pennsylvania: - Lehigh Valley Hospital-Cedar Crest — Allentown, Pennsylvania
- Lehigh Valley Hospital - Muhlenberg — Bethlehem, Pennsylvania
- Geisinger Medical Center — Danville, Pennsylvania
- Pocono Medical Center — East Stroudsburg, Pennsylvania
- Lehigh Valley Hospital-Hazleton — Hazleton, Pennsylvania
Phase 3 Recruiting Industry
The purpose of this study is to learn about the study medicine called elranatamab.This study aims to compare elranatamab to other medicines for the treatment of MM (a type of cancer). This study is seeking participants who: * Are 18 years …
Sponsor: Pfizer
NCT ID: NCT06152575
Sites in Pennsylvania: - AHN West Penn Hospital — Pittsburgh, Pennsylvania
Phase 3 Recruiting Industry
The purpose of this study is to compare the efficacy of teclistamab in combination with daratumumab and lenalidomide (Tec-DR) and talquetamab in combination with daratumumab and lenalidomide (Tal-DR) versus daratumumab, lenalidomide, dexam…
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT05552222
Sites in Pennsylvania: - Penn State Milton S Hershey Medical Ctr — Hershey, Pennsylvania
- Allegheny Health Network — Pittsburgh, Pennsylvania
Phase 3 Recruiting Industry
The purpose of this study is to compare the efficacy and safety of mezigdomide (CC-92480), bortezomib and dexamethasone (MeziVd) versus pomalidomide, bortezomib and dexamethasone (PVd) in participants with relapsed or refractory multiple m…
Sponsor: Celgene
NCT ID: NCT05519085
Sites in Pennsylvania: - Lehigh Valley Health Network — Allentown, Pennsylvania
- Local Institution - 0264 — York, Pennsylvania
Phase 3 Recruiting Industry
The purpose of this study is to compare the effectiveness of either talquetamab plus pomalidomide (Tal-P) or talquetamab plus teclistamab (Tal-Tec) with elotuzumab, pomalidomide, and dexamethasone (EPd) or pomalidomide, bortezomib, and dex…
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT06208150
Sites in Pennsylvania: - Penn State Milton S Hershey Medical Ctr — Hershey, Pennsylvania
- Thomas Jefferson University — Philadelphia, Pennsylvania
- West Penn Hospital — Pittsburgh, Pennsylvania
- University Of Pittsburgh Medical Center UPMC Hillman Cancer Center — Pittsburgh, Pennsylvania
Phase 3 Recruiting Industry
The purpose of this study is to compare the effectiveness of iberdomide maintenance to lenalidomide maintenance therapy after autologous stem cell transplantation (ASCT) in participants with newly diagnosed multiple myeloma (NDMM).
Sponsor: Bristol-Myers Squibb
NCT ID: NCT05827016
Sites in Pennsylvania: - Thomas Jefferson University Hospital — Philadelphia, Pennsylvania
- Fox Chase Cancer Center - Jeanes Campus — Philadelphia, Pennsylvania
- University of Pittsburgh - Hillman Cancer Center — Pittsburgh, Pennsylvania
Phase 3 Recruiting Network
This is a multicenter, randomized, open-label, Phase 3 study in participants with newly diagnosed multiple myeloma to evaluate the benefits of teclistamab in combination with lenalidomide and teclistamab alone versus lenalidomide alone as …
Sponsor: European Myeloma Network B.V.
NCT ID: NCT05243797
Sites in Pennsylvania: - Lehigh Valley Health Network — Allentown, Pennsylvania
- Penn Medicine Lancaster General — Lancaster, Pennsylvania
- Abramson Cancer Center University of Pennsylvania Medical Center — Philadelphia, Pennsylvania
- Fox Chase Cancer Center — Philadelphia, Pennsylvania
- UPMC Hillman Cancer Center — Pittsburgh, Pennsylvania
Phase 3 Recruiting Industry
The purpose of this study is to compare the efficacy and safety of arlo-cel (BMS-986393) versus standard regimens in adult participants with Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma.
Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
NCT ID: NCT06615479
Sites in Pennsylvania: - Fox Chase Cancer Center — Philadelphia, Pennsylvania
- Local Institution - 0232 — Pittsburgh, Pennsylvania
Phase 3 Recruiting Industry
The purpose of this study is to evaluate how well JNJ-79635322 works when compared with an anti-B-cell maturation antigen (BCMA)xCD3 bispecific antibody.
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT07258511
Sites in Pennsylvania: - Thomas Jefferson University Hospital — Philadelphia, Pennsylvania
Phase 2 Recruiting Academic/Other
The purpose of the study is to learn from the real world practice of prescribing targeted therapies to patients with advanced cancer whose tumor harbors a genomic variant known to be a drug target or to predict sensitivity to a drug. NOTE:…
Sponsor: American Society of Clinical Oncology
NCT ID: NCT02693535
Sites in Pennsylvania: - Lehigh Valley Hospital - Cedar Crest — Allentown, Pennsylvania
- Lehigh Valley Hospital- Muhlenberg — Bethlehem, Pennsylvania
- Pocono Medical Center — East Stroudsburg, Pennsylvania
- Lehigh Valley Hospital-Hazleton — Hazleton, Pennsylvania
- Fox Chase Cancer Center — Philadelphia, Pennsylvania
Phase 2 Recruiting NIH
This phase II trial compares iberdomide maintenance therapy to disease monitoring for improving survival in patients who have received idecabtagene vicleucel (a type of chimeric antigen receptor T-cell \[CAR-T\] therapy) for multiple myelo…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06179888
Sites in Pennsylvania: - Geisinger Medical Center — Danville, Pennsylvania
Phase 2 Recruiting Industry
The purpose of this study is to evaluate the effectiveness and safety of Arlocabtagene Autoleucel (BMS-986393) in participants with relapsed or refractory multiple myeloma.
Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
NCT ID: NCT06297226
Sites in Pennsylvania: - Local Institution - 0070 — Philadelphia, Pennsylvania
Phase 1, Phase 2 Recruiting Industry
A phase 1/2 dose escalation / dose expansion study of Enzomenib (DSP-5336) in patients with acute leukemia.
Sponsor: Sumitomo Pharma America, Inc.
NCT ID: NCT04988555
Sites in Pennsylvania: - Sidney Kimmel Comprehensive Cancer Center — Philadelphia, Pennsylvania
- Allegheny Health Network — Pittsburgh, Pennsylvania
Phase 2 Recruiting Industry
The purpose of this study is to evaluate how well JNJ-79635322 works (efficacy) in participants with Relapsed or Refractory Multiple Myeloma (RRMM; a cancer that forms in a type of white blood cells called a plasma cell. Cancer is called r…
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT07266441
Sites in Pennsylvania: - University of Pennsylvania — Philadelphia, Pennsylvania
Phase 1, Phase 2 Recruiting Industry
The purpose of this study is to evaluate the safety and tolerability of mRNA-2808 in participants with relapsed or refractory multiple myeloma (RRMM).
Sponsor: ModernaTX, Inc.
NCT ID: NCT07116616
Sites in Pennsylvania: - Penn Medicine — Philadelphia, Pennsylvania
Phase 1, Phase 2 Recruiting Industry
This is a Phase I/II, modular, open-label, multicenter, dose escalation, and dose expansion/optimization study to evaluate the safety, tolerability, PK, immunogenicity, pharmacodynamics, and preliminary efficacy of AZD0305 in participants …
Sponsor: AstraZeneca
NCT ID: NCT06106945
Sites in Pennsylvania: - Research Site — Philadelphia, Pennsylvania
Phase 1, Phase 2 Recruiting Industry
A Phase 1/2a study to assess the safety, tolerability, PK and biological activity of CCS1477 (inobrodib) in patients with Non-Hodgkin Lymphoma, Multiple Myeloma, Acute Myeloid Leukaemia or High Risk Myelodysplastic syndrome.
Sponsor: CellCentric Ltd.
NCT ID: NCT04068597
Sites in Pennsylvania: - Penn Medicine - Abramson Cancer Center Perelman — Philadelphia, Pennsylvania
Phase 2 Recruiting Industry
This study is researching an investigational drug called linvoseltamab ("study drug") in participants at moderate risk of developing multiple myeloma (about 3 to 10% average annual risk), a group that consists of patients with precancerous…
Sponsor: Regeneron Pharmaceuticals
NCT ID: NCT06140524
Sites in Pennsylvania: - Thomas Jefferson University Hospital — Philadelphia, Pennsylvania
Phase 2 Recruiting Academic/Other
This is a single-arm, non-inferiority study in which patients who have achieved a very good partial response (VGPR) or better, according to International Myeloma Working Group (IMWG) response criteria, following 6 to 9 months of treatment …
Sponsor: Abramson Cancer Center at Penn Medicine
NCT ID: NCT05932680
Sites in Pennsylvania: - Abramson Cancer Center at University of Pennsylvania — Philadelphia, Pennsylvania
- Thomas Jefferson University, Honickman Center — Philadelphia, Pennsylvania
Phase 2 Recruiting Industry
The purpose of this study is to learn more about the anti-cancer activity of inobrodib, when given in combination with pomalidomide and dexamethasone, in patients with multiple myeloma that has come back following treatment and which no lo…
Sponsor: CellCentric Ltd.
NCT ID: NCT07096778
Sites in Pennsylvania: - University of Pennsylvania, Abramson Cancer Center — Philadelphia, Pennsylvania
Phase 2 Recruiting Academic/Other
This prospective trial investigates the approach of G-CSF with risk-adapted Plerixafor use for stem cell mobilization in patients undergoing autologous stem cell transplantation. Since FDA approval in 2008, Plerixafor has been combined wit…
Sponsor: Thomas Jefferson University
NCT ID: NCT07188090
Sites in Pennsylvania: - Thomas Jefferson University Hospital — Philadelphia, Pennsylvania
Phase 2 Recruiting Academic/Other
This phase II clinical trial evaluates whether a modified modality of conditioning reduces treatment-related mortality (TRM) in patients who undergo a hematopoietic stem cell transplant (HSCT) for a hematological malignancy. HSCT is a cura…
Sponsor: Thomas Jefferson University
NCT ID: NCT05031897
Sites in Pennsylvania: - Sidney Kimmel Cancer Center at Thomas Jefferson University — Philadephia, Pennsylvania
Phase 1 Recruiting Industry
Phase 1 study comprised of open-label, dose escalation, multiple cohorts of P-BCMA-ALLO1 allogeneic T stem cell memory (Tscm) CAR-T cells in subjects with relapsed / refractory Multiple Myeloma (RRMM).
Sponsor: Poseida Therapeutics, Inc.
NCT ID: NCT04960579
Sites in Pennsylvania: - University of Pennsylvania — Philadelphia, Pennsylvania